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Background: The resistance of human malaria parasites to anti-malarial compounds has become considerable
concern, particularly in view of the shortage of novel classes of anti-malarial drugs. One way to prevent resistance is
by using new compounds that are not based on existing synthetic antimicrobial agents.
Results: Sensitivity of 100 Plasmodium falciparum isolates to chloroquine, quinine, amodiaquine, mefloquine,
sulphadoxine/pyrimethamine, artemisinin, Momordica charantia (‘Ejirin’) Diospyros monbuttensis (‘Egun eja’) and
Morinda lucida (‘Oruwo’) was determined using the in vitro microtest (Mark III) technique to determine the IC50 of
the drugs. All the isolates tested were sensitive to quinine, mefloquine and artesunate. Fifty-one percent of the
isolates were resistant to chloroquine, 13% to amodiaquine and 5% to sulphadoxine/pyrimethamine. Highest
resistance to chloroquine (68.9%) was recorded among isolates from Yewa zone while highest resistance to
amodiaquine (30%) was observed in Ijebu zone. Highest resistance to sulphadoxine/pyrimethamine was recorded in
Yewa and Egba zones, respectively. A positive correlation was observed between the responses to artemisinin and
mefloquine (P<0.05), artemisinin and quinine (P<0.05) and quinine and mefloquine (P<0.05). A negative correlation
was observed between the responses to chloroquine and mefloquine (P>0.05). Highest anti-plasmodial activity was
obtained with the ethanolic extract of D. monbuttensis (IC50 = 3.2nM) while the lowest was obtained from M. lucida
(IC50 =25nM).
Conclusions: Natural products isolated from plants used in traditional medicine, which have potent anti-plasmodial
action in vitro, represent potential sources of new anti-malarial drugs.
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The main cause of the worsening malaria situation in re-
cent years has been the spread of drug-resistant para-
sites. This has led to rising malaria-associated mortality
[1]. Anti-malarial drug resistance has emerged as one of
the greatest challenges facing malaria control today and
has also been implicated in the spread of malaria to new
areas and re-emergence of malaria in areas where the
disease had been eradicated [2,3]. Drug resistance has* Correspondence: grace.olasehinde@covenantuniversity.edu.ng
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distribution, and reproduction in any mediumalso played a significant role in the occurrence and se-
verity of epidemics in some parts of the world. Popula-
tion movement has introduced resistant parasites to
areas previously free of drug resistance. Moreover, in re-
cent years the situation has worsened due to malaria
parasites becoming resistant to several anti-malarial
drugs [4,5]. This resistance concerns numerous drugs,
but is thought to be most serious with chloroquine
(CQ), the cheapest and most widely used drug to treat
malaria [6].
The use of plants for therapeutic purposes has long
been in practice [7]. Medicinal plants have been used in
virtually all cultures as a source of medicine [8] and fortral Ltd. This is an Open Access article distributed under the terms of the
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medication [9]. Several medicinal plants have been used
locally to treat malaria infection. Medicinal plants, such
as Momordica charantia (local name: Ejirin wewe),
Momordica balsamina (local name: Ejirin), Ageratum
conyzoides (local name: Imi Eshu), Diospyros monbutten-
sis (local name, Egun Eja), have been used to treat one
ailment or the other in Africa, especially Nigeria [10-12].
The urgency generated by drug-resistant strains of
malaria parasites has accelerated anti-malarial drug re-
search over the last two decades. While synthetic
pharmaceutical agents continue to dominate research,
attention has increasingly been directed to natural prod-
ucts [13]. The success of quinine (QN) and artemisinin,
isolated from Artemisia annua and its derivatives, for
the treatment of resistant malaria has focused attention
on plants as a source of anti-malarial drugs [14].
Moreover, plants have been the basic source of so-
phisticated traditional medicine systems for thousands
of years and were instrumental in early pharmaceut-
ical drug discovery and industry [15]. The world’s
poorest are the worst affected, and many treat them-
selves with traditional herbal medicines. These are
often more available and affordable, and sometimes
are perceived as more effective than conventional
anti-malarial drugs [16].
Ethnobotanical information about anti-malarial plants
used in traditional herbal medicine is essential for fur-
ther evaluation of the efficacy of plant anti-malarial rem-
edies, and efforts are now being directed towards
discovery and development of new, chemically diverse
anti-malarial agents [17]. Several rural dwellers depend
on traditional herbal medicine for treatment of many in-
fectious diseases [18]. The reputed efficacies of these
plants have been experienced and passed on from one
generation to the other.
About 75% of the population in Africa does not have
direct access to conventional medicine for malaria treat-
ment but they do have access to traditional medicine for
treating fevers. Treatment with these remedies has suf-
fered a number of deficiencies; identification of plant ex-
tracts may be insecure and the chemical content of
extracts may vary considerably [11]. Natural products
isolated from plants used in traditional medicine, which
have potent anti-plasmodial action in vitro, represent
potential sources of new anti-malarial drugs [19,20]. It
had been advocated that direct crude drug formulation
of the herbs following toxicological absolution (after it
has been ascertained to be non-toxic) may not only pro-
duce dosage forms faster but will also lead to cheaper
and more affordable drugs for the communities that
need them [21]. This research was carried out in order
to increase the database of plants whose extracts can be
used in the treatment of malaria.Methods
Study area
The study was carried out in Ogun State, south-western
Nigeria. The state has a total land mass of 16,409.26 sq
km and shares an international boundary with the
Republic of Benin to the west and interstate boundaries
with Oyo State to the north, Lagos and the Atlantic
Ocean to the south and Ondo State to the east (Figure 1).
For the purpose of this study, the state was grouped into
zones based on the origin of the people, namely, Egba,
Ijebu, Yewa/Awori and Remo. One major town from
each of these zones (Abeokuta, Ijebu-Ode, Sango-Otta
and Sagamu, in that order) was used as a study site.
Abeokuta, the capital of Ogun State, lies between lati-
tude 70 10′ N and 70 15′ N and longitudes 30 17′ E
and 30 26′ E. Ijebu-Ode lies between 6° 49' N, 3° 56' E.
Sango-Otta is situated within the tropical zone, lying be-
tween 60° and 47° N of the Equator and 20.33° E and
30.18° E while Sagamu has its geographical coordinates
as 6° 51' N, 3° 39' E. Cultured isolates of Plasmodium
falciparum, totalling 100 in all, were collected from all
four towns.
Sample collection
State general hospitals located in the different zones
were used as collection centres. Both in- and outpatients
who presented with uncomplicated malaria in the hospi-
tals were recruited for the research work. Blood of the
patients was collected using heparin bottles. Subjects
were screened according to exclusion/inclusion criteria.
Samples used for the study were collected from subjects
who had received QN and artemisinin derivatives within
the previous seven days, 4-aminoquinolones within the
previous 14 days, pyrimethamine or sulphonamides
within 28 days or mefloquine within the previous 56
days of blood collection. Blood samples were collected
for malaria screening by fingerprick and venipuncture in
order to check the presence of asexual parasites in the
peripheral smear of patients. Safety procedures were
adopted in the collection of fingerprick samples by
swabbing the area to be sampled with 70% alcohol and
allowing it to dry before collection. The bleeding was
done in the hospitals by clinicians and medical labora-
tory scientists. About 2–5 ml of blood was drawn
(venipuncture) using a sterile disposable syringe. The
blood samples were collected between April 2008 and
June 2009.
Patients’ characteristics
A total of 4,066 subjects comprising 1,839 males and
2,227 females presenting with malaria in four different
zones of Ogun State were recruited into the study. The
total number of subjects recruited in Sango-Otta, Abeokuta,
Ijebu-Ode and Sagamu were 1,120, 1,116, 995 and 835,
Figure 1 Map of Ogun State, Southwestern Nigeria.
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nant women and other adults were included in this
study. This is because the majority of malaria cases
occur in children under the age of 12 years; pregnant
women are also especially vulnerable. The mean age
was 19 years, with 93% less than 25 years old.
Ethical consideration
Scientific and ethical clearance for this work was ob-
tained from the Nigerian Institute of Medical Research –
Institutional Review Board (NIMR-IRB) and Covenant
University Ethics Committee. The Ogun State Ministry
of Health (Hospitals Management Board) was also in-
formed and clearance obtained for this study. Written
informed consent was obtained from patients prior to
recruitment into this study. Consent for children was
provided by parents/guardians while some participants
provided the assents.Microscopic examination
Giemsa-stained thick and thin films were prepared for
the microscopic examination of the malaria parasite.
The thin films were fixed with methanol and all films
were stained with 3% Giemsa stain of pH 7.0 for 30 min
as recommended by WHO [22]. Blood films were exam-
ined microscopically using 100X (oil immersion) objec-
tives as described by Cheesbrough [23]. The thick films
were used to determine the parasite densities while thin
films were used to identify the parasite species and in-
fective stages. Parasite density per microlitre of blood
(parasitaemia) was estimated from the thick film, taking
the number of leucocytes per microlitre of blood as
8,000.
Cryopreservation
The infected blood was centrifuged at 959 × g. The
supernatant/plasma was removed and cells were suspended
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distributed into cryotubes and quickly frozen in cryofreezer
at −80°C and then transferred into liquid nitrogen (−196°C).
The cryopreservative was prepared by adding 28 ml glycerol
to 72 ml of 4.2% Sorbitol in normal saline. The solution was
sterilized by filtration through a Millipore filter of 0.22 μm
porosity.
Cultivation of parasites
The vial was taken out of the liquid nitrogen tank and
thawed quickly in a 37°C water bath. The content was
transferred to a centrifuge tube and centrifuged at 959 ×
g for 10 min. The supernatant was then removed and an
equal volume of 3.5% NaCl was added. The suspension
was centrifuged again and the supernatant removed. The
pellet was washed twice with complete medium supple-
mented with 15% serum (Albumax). The parasites were
cultured using a candle jar in RPMI 1640 medium sup-
plemented with gentamicin solution at 0.01 mg/mL, 25
mM HEPES buffer, 25 mM NaHCO3, and 1% Albumax
II maintained in 5% CO2 and incubated at 37°C. The
estimation of the parasitaemia, as well as parasite
visualization before incubation, was done using Giemsa
stained blood films on normal light microscopes.
Preparation of plant extract
Leaves of plants were used. The plants were identified in
the Department of Pharmacognosy, Lagos University
Teaching Hospital, Lagos. Ten grams of dried extract
was dissolved in 50 ml alcohol (95%) 37°C for seven days
at room temperature. The alcohol was allowed to evap-
orate at room temperature. Ten millilitres dimethyl
sulphoxide (DMSO) was added to 10 mg of each extract
to make 1 mg/ml.
In vitro test
The overall incidence of falciparum malaria as deter-
mined by microscopy in the study area was 62.7%
(2,250/4,066). Out of the P. falciparum samples col-
lected, 100 isolates were successfully cultured and main-
tained in continuous culture for a minimum of three
weeks. Drug samples were prepared in picomole/litre
(pM) quantities according to WHO in vitro microtest
procedure [24,25]. The assay was performed in duplicate
in a 96-well microplate, according to WHO method
(in vitro microtest (Mark III)), which is based on asses-
sing the inhibition of schizont maturation. RPMI 1640
(Gibco BRL, Paisley, UK) was the culture medium used
for cultivation of P. falciparum [26]. Dilution was pre-
pared from the anti-malarial drugs. 1% DMSO was used
to prepare the drug stock. Also a control was set up
where only the solvent was present in the well and the
parasites were able to undergo schizogony in the control
well. Stock solutions of chloroquine sulphate (600 ng/ml)and other anti-malarial drugs (amodiaquine (AQ) = 119
ng/ml, mefloquine (MQ) = 265 ng/ml, quinine (QN) =
462 ng/ml, artesunate (AS) = 360 ng/ml, all prepared ac-
cording to World Health Organisation’s Standard Operating
Procedures were prepared in sterile distilled water (CQ,
AQ, MQ and Q or ethanol (sulphadoxine/pyrimeth-
amine (SP) and artemisinin) and used in two-fold dilu-
tions with the culture medium in 96-well culture
microplates (Nunc, Denmark) to obtain nine final dilu-
tions (600 to 2.34 ng/ml for CQ) and appropriate dilu-
tion factor was determined for the other drugs and the
crude plant extracts and the final concentrations pre-
pared by serial dilution were (125, 62.5, 31.25, 15.6, 7.8,
3.9 and 1.95 μg/ml). Negative controls treated by solv-
ent and positive controls (25 nmol/L chloroquine phos-
phate) were added to each set of experiments for the
herbal extracts. Fifty μl which is the final volume per
test well, from the parasitized blood mixture media was
added to each well in plate and incubated in CO2 con-
dition; 5% CO2 at 37.5°C for 24–30 hours. After incu-
bation, contents of the wells were harvested and
stained for 30 min in a 2% Giemsa solution pH 7.2;
after that, the developed schizonts were counted
against the total asexual parasite count of 200. The
count process was done in duplicate, and the data were
analysed by using HN-NonLin V1.1 [27] to determine
the IC50. The IC50 value is defined as the concentration
of an anti-malarial drug that inhibits 50% of schizont
maturation as compared with the development in drug-
free control wells. IC99 gives a result that closely approxi-
mates a minimum inhibitory concentration (MIC). The
MIC is generally defined as the lowest drug concentration
that inhibits the development of rings to schizonts.
Statistical analysis
Data were analysed using Chi-square and ANOVA stat-
istical tests. All the tests were performed at the 95% con-
fidence interval using SPSS version 15.0 software.
Results
In vitro anti-malarial drugs and local herbal extracts sen-
sitivity tests were carried out and the IC50 and IC99 for
each drug were determined. Table 1 shows the mean
IC50 and IC99 values for CQ, AQ, MQ, QN, SP and As.
Moreover, the in vitro threshold values for anti-malarials
have been defined [28]. IC50 implies that 50% of the
parasite could not mature to schizont stage at that drug
concentration while IC99 implies that the anti-malarial
drugs inhibited 99% of the parasites from maturing to
schizont stage at that concentration.
All the selected isolates tested were sensitive to QN,
MQ and AS while in vitro resistance was observed in
CQ, AQ and SP (Table 2). Highest percentage of resist-
ance to CQ (69.8%) was recorded among isolates from
Table 1 In vitro susceptibility of Plasmodium falciparum
isolates to anti-malarial drugs
Drug IC50 mean
(nM)
IC99 mean
(nM)
Resistance
threshold (nM)
Chloroquine (CQ) 24.4 164.2 > 160
Amodiaquine (AQ) 6.3 32.4 > 80
Artesunate (AS) 3.2 7.8 > 10.5
Mefloquine (MQ) 42.1 60.8 > 64.0
Sulphadoxine/
Pyrimethamine (SP)
55.0 200 > 300
0.7 2.5 > 4.0
Quinine (Q) 60.3 298.6 > 300
Table 3 In vitro susceptibility of Plasmodium falciparum
isolates to local anti-malarial herbs
Herbal Drug IC50 nM
Momordica charantia (Ejirin) 12.5
Morinda lucida (Oruwo) 25
Diospyros monbuttensis (Eegun eja) 3.2
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(30%) was observed in Ijebu zone. Highest percentage of
resistance against SP (10%) was recorded in Yewa and
Egba zones. A positive correlation was observed between
the responses to artemisinin and MQ (P<0.05), artemisi-
nin and Q (P<0.05), QN and MQ (P<0.05) (Table 2). A
negative correlation was observed between the responses
to CQ and MQ (P>0.05).
The results of in vitro anti-malarial activity of the
three herbal extracts tested -are as shown in Table 3. Of
the selected three herbal extracts, the highest activity
was obtained with extract of D. monbuttensis (IC50 = 3.2
nM) while the lowest was obtained from M. lucida
(IC50 =25nM). In vitro resistance against CQ, AQ and
SP was observed among Nigerian isolates of P. falcip-
arum tested. In the cross-sectional study, an IC50 of
24.4 nM and IC99 of 164.2 nM was recorded for CQ re-
spectively Moreover, resistance threshold of isolates
against sulphadoxine and pyrimethamine was 300 nM
and 4.0 nM, respectively. All the isolates tested against
MQ, QN and AS in this study were sensitive to the
drugs. The sensitivity range observed in the current
study was also within the range for sensitivity of iso-
lates to the drug [28]. In vivo resistance against CQ,
AQ, MQ and SP has been reported by researchers in
Nigeria [29,30]. The in vivo response of P. falciparum
to anti-malarial drugs is modulated by a number of fac-
tors. These include the pharmacokinetic properties of
anti-malarial drugs, innate and acquired immunity in
the patient, as well as the complexity of infections in
high transmission areas [29]. Several of these factors mayTable 2 Zone-wise resistance pattern of Plasmodium falciparu
Origin Number of isolates cultured CQ res (%) AQ res (
Ijebu 20 9 (45) 6 (30)
Yewa 43 30 (69.8) 4 (9.3)
Egba 25 5 (20) 1 (4)
Remo 12 7 (58.3) 2 (16.7)
Total 100 51 (51) 13 (13)
CQ - chloroquine; AQ - amodiaquine; As - artesunate; MQ - mefloquine; SP - sulphacontribute to the range of variations in the clinical expres-
sion of CQ resistance and in vitro resistance patterns.
All the isolates tested in vitro against artemisinin were
sensitive to the artesunate, a derivative of artemisinin.
Bioavailability of artemisinin derivatives in vivo amongst
other factors has been attributed to treatment failures
[31]. AS, which is a derivative of artemisinin, was used
for the in vitro drug testing in this study because it has
been reported that dihydroartemisinin is unstable on
drug plates and that artesunate is the most appropriate
drug for in vitro drug assays due to its stability in pre-
dosed plates [32].
High resistance against CQ and AQ were observed
among the isolates collected from Yewa and Ijebu zones
while SP resistance was not observed in isolates from
Remo zone. There was cross-resistance between CQ and
AQ as some of the isolates that showed resistance to CQ
also showed resistance to AQ in all the zones. Cross-
resistance between CQ and AQ has been reported both
in vitro and in vivo. Pradines et al. [33] have observed
cross-resistance of CQ and AQ in earlier studies. It has
also been observed that parasites may quickly develop
resistance to AQ in areas where extensive CQ resistance
has been documented [34].
There is an increasing acceptance that the ideal
approach to anti-malarial treatment is the use of a com-
bination of two or more drugs, rather than a single anti-
malarial drug, preferably with an artemisinin derivative as
one of the drugs [28,35]. AQ in combination with AS has
been introduced as first-line treatment of malaria to re-
place CQ in Nigeria and other malaria-endemic countries
of Africa [36]. Although the role of AS in this combination
is to prevent the development of amodiaquine resistance,
parasites may quickly develop resistance to AQ in areas
where extensive CQ resistance has been documented.
In addition, little is known about the mechanism orm to anti-malarial drugs
%) As res (%) MQ res (%) SP res (%) Q res (%)
0 (0) 0 (0) 1 (5) 0 (0)
0 (0) 0 (0) 2 (10) 0 (0)
0 (0) 0 (0) 2 (10) 0 (0)
0 (0) 0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 5 (5) 0 (0)
doxine/pyrimethamine; Q - quinine; res - resistance.
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then likely recrudesce under the selective force of the sec-
ond drug in the combination and be transmitted to mos-
quitoes [37]. Therefore, the possibility of increasing
selection of AQ-resistant parasites with the increasing use
of AQ in combination with AQ in Nigeria cannot be ruled
out. Reduced in vitro susceptibility is not synonymous
with diminished therapeutic effectiveness, but it is the
probable first step of an alarming cascade and definitely
pleads for increased vigilance and a coordinated and rapid
deployment of drug combinations.
Developing countries, where malaria is one of the
most prevalent diseases, still rely on traditional medicine
as a source for the treatment of this disease. While syn-
thetic pharmaceutical agents continue to dominate re-
search, increasing attention has been directed to natural
products [38]. The success of artemisinin, isolated from
Artemisia annua, and its derivatives for the treatment of
resistant malaria has focused attention on plants as a
source of anti-malarial drugs [14]. In this study, three
crude organic extracts obtained from medicinal plants
used in Nigerian folk medicine for the treatment of fever
and malaria were tested in vitro against P. falciparum.
Diospyros monbuttensis showed appreciable inhibition to
the parasites at all the concentrations used and an IC50
of 3.2 nM in the study. Diospyros monbuttensis, which is
locally used for the treatment of fevers, headaches and
stomach disorders [10,11], has not been widely studied.
This study represents the first conducted for anti-
malarial activity of crude extracts of D. monbuttensis.
The results confirm that these plants, which are used
in traditional medicine against malaria, may possess
in vitro and significant anti-malarial potential and jus-
tify their use in traditional medicine. This observation
suggests that the active constituents in the extract may
be cytotoxic for P. falciparum trophozoites, thereby
inhibiting their development to the schizont stage.
An IC50 observed for M. charantia in this study was
12.5 nM. These observations suggest that the active constit-
uents in the extract might also be cytotoxic for P. falcip-
arum trophozoites, thereby inhibiting their development to
the schizont stage. The anti-malarial activity of M. charan-
tia has been previously reported [38]. They found that the
aqueous extract of M. charantia leaves showed IC50 values
less than 100 μg/ml which is in agreement with the obser-
vations in this study; the methanolic extract showed moder-
ate activity with IC50 = 12.5 nM. Morinda lucida also
exhibited anti-malarial activity in this study. The IC50 of 25
nM observed in this study is comparable with other studies.
Also for M. lucida, dose-dependent inhibitory outcomes
were marked. Awe and Makinde [10], reported the dose-
dependent and seasonal variation in the activity of M.
lucida using both in vitro and in vivo techniques. Morinda
lucida was reported to contain anthraquinones, whichshowed in vitro activity against P. falciparum and also pos-
sess antifungal properties. Morinda lucida is used locally in
the treatment of yellow fever and jaundice [39].
Conclusions
In vivo studies on these medicinal plants are necessary
and should seek to determine toxicity of the active con-
stituents, their side effects, serum-attainable levels, phar-
macokinetic properties and diffusion in different body
sites. Additional pharmacokinetic investigations are there-
fore advisable to identify host-related factors, such as poor
absorption, accelerated gastrointestinal passage of the test
drug, or metabolic peculiarities of some patients, which
might lead to a faster-than-normal inactivation or elimin-
ation of the test drug.
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